Shares of MacroGenics Inc. (NASDAQ:MGNX) fell 1.9% during mid-day trading on Friday . The company traded as low as $31.11 and last traded at $31.75, with a volume of 109,807 shares. The stock had previously closed at $32.35.

A number of brokerages recently issued reports on MGNX. Citigroup Inc. downgraded shares of MacroGenics from a “buy” rating to a “neutral” rating and increased their price target for the stock from $27.00 to $32.00 in a report on Thursday. Zacks Investment Research raised shares of MacroGenics from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. Morgan Stanley reissued a “hold” rating on shares of MacroGenics in a report on Thursday, June 30th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of MacroGenics in a report on Tuesday, June 14th. Finally, BTIG Research reissued a “buy” rating and set a $35.00 price target on shares of MacroGenics in a report on Sunday, May 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $38.71.

The company’s market cap is $1.09 billion. The stock’s 50-day moving average is $27.57 and its 200-day moving average is $21.90.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $1.14. During the same period in the previous year, the firm posted ($0.71) EPS. The firm earned $80.67 million during the quarter, compared to analyst estimates of $27.22 million. The company’s revenue for the quarter was up 1100.4% compared to the same quarter last year. On average, analysts predict that MacroGenics Inc. will post ($1.97) EPS for the current year.

In other news, SVP Jon Marc Wigginton sold 20,000 shares of the company’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $30.78, for a total transaction of $615,600.00. Following the completion of the transaction, the senior vice president now owns 20,000 shares of the company’s stock, valued at approximately $615,600. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Lynn Cilinski sold 8,922 shares of the company’s stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $27.22, for a total transaction of $242,856.84. Following the transaction, the vice president now directly owns 10,845 shares of the company’s stock, valued at approximately $295,200.90. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently bought and sold shares of the stock. Jennison Associates LLC increased its position in MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock worth $8,282,000 after buying an additional 909 shares in the last quarter. California State Teachers Retirement System increased its position in MacroGenics by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 58,401 shares of the biopharmaceutical company’s stock worth $1,809,000 after buying an additional 1,038 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock worth $1,386,000 after buying an additional 20,929 shares in the last quarter. Finally, Marshall Wace LLP increased its position in MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock worth $2,902,000 after buying an additional 45,422 shares in the last quarter.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.